Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary cutaneous T-cell lymphomas.

Steven T Rosen1, Christiane Querfeld

  • 1Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 710 N Fairbanks Ct, Olson Pavilion, Suite 8-250, Chicago IL 60611-2645, USA. s-rosen@northwestern.edu

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiopaque microsphere-hydrogel composite for extended-release intratumoral immunotherapy in a large animal model.

Drug delivery and translational research·2026
Same author

Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials.

The Lancet. Oncology·2026
Same author

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia.

Blood·2026
Same author

Molecular Genetic Demonstration of the Evolution of Transformed Mycosis Fungoides: A Clinicopathological and Molecular Case Study.

Journal of cutaneous pathology·2026
Same author

Mogamulizumab-associated lymphadenopathy masquerading as lymphoma progression.

JAAD case reports·2026
Same author

Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Primary cutaneous T-cell lymphomas (CTCLs) are diverse skin cancers involving malignant T lymphocytes. This review covers common CTCL subtypes, their unique features, and treatment strategies based on disease stage.

Area of Science:

  • Dermatology
  • Hematology
  • Oncology

Background:

  • Primary cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas (NHLs).
  • CTCLs are characterized by the clonal proliferation of malignant T lymphocytes and natural killer cells that home to the skin.
  • They represent a significant proportion, 75-80%, of all cutaneous lymphomas.

Purpose of the Study:

  • To review the most common subtypes of CTCLs.
  • To discuss the unique biological characteristics and clinical courses of these subtypes.
  • To outline current therapeutic approaches for CTCLs.

Main Methods:

  • Review of current literature and classification systems (WHO-EORTC).
  • Focus on the most prevalent CTCL entities.

Related Experiment Videos

  • Discussion of disease staging and progression in relation to treatment.

    • Main Results:

    • CTCLs encompass 13 distinct entities according to the WHO-EORTC classification.
    • Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, and lymphomatoid papulosis constitute approximately 95% of CTCLs.
    • Each major subtype exhibits distinct biological and clinical profiles.

    Conclusions:

    • Understanding the heterogeneity of CTCLs is crucial for accurate diagnosis and management.
    • Therapeutic strategies are tailored to the specific subtype, disease stage, and progression rate.
    • Further research into the unique characteristics of each CTCL entity will refine treatment protocols.